TTPH : Summary for Tetraphase Pharmaceuticals, Inc - Yahoo Finance

U.S. Markets close in 5 hrs 57 mins

Tetraphase Pharmaceuticals, Inc. (TTPH)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.17-0.08 (-1.88%)
As of 10:02AM EST. Market open.
People also watch
CEMPCMRXESPRPTCTZFGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.25
Open4.24
Bid4.15 x 2300
Ask4.18 x 400
Day's Range4.16 - 4.26
52 Week Range3.11 - 6.28
Volume45,838
Avg. Volume395,356
Market Cap153.89M
Beta2.74
PE Ratio (TTM)-2.09
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI

    WATERTOWN, Mass., Jan. 17, 2017-- Tetraphase Pharmaceuticals, Inc. today announced dosing of the first patient in IGNITE3, the Company’ s phase 3 clinical trial evaluating the efficacy and safety of once-daily ...

  • American City Business Journals14 days ago

    Deloitte leads the way in Massachusetts IPO auditing work in 2016

    Deloitte won more auditing work from Massachusetts businesses going public last year than any other accounting firm, landing jobs with a third of the companies that underwent initial public offerings statewide. The firm’s Boston office audited three biotech companies — Syndax Pharmaceuticals (SNDX), Intellia Therapeutics (NTLA) and Ra Pharmaceuticals (RARX) — and the tech company Acacia Communications (ACIA) in the leadup to their 2016 IPOs. Massachusetts was home to 12 IPOs last year, according to Renaissance Capital, a manager of IPO-focused exchange-traded funds.

  • GlobeNewswirelast month

    Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline

    –Company to Submit MAA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections to the EMA in Second Half of 2017–. –Phase 3 IGNITE3 Study in Complicated Urinary Tract Infections to ...